Market Place
Sourcing Support
Triumvira Immunologics to Present Clinical Data at the 2024 ASCO
19 Dec 2023 //
PR NEWSWIRE
Triumvira shares upcoming plans for accelerated approval with cell therapies
14 Jun 2023 //
CLINICAL TRIALS ARENA
Triumvira Announces Updated Data from Ongoing TACTIC?2 Trial of TAC01-HER2
11 Nov 2022 //
BIOSPACE
Triumvira Demonstrates Strength of Preclinical Research Pipeline at SITC 2022
10 Nov 2022 //
BUSINESSWIRE
Triumvira Immunologics to Present Clinical and Preclinical Updates at SITC
27 Oct 2022 //
BUSINESSWIRE
Triumvira Appoints Life Sciences Industry Leader Robert Williamson as President
25 Oct 2022 //
BUSINESSWIRE
Triumvira Immunologics Enters Multi-Year Agreement with AmplifyBio
19 Oct 2022 //
CONTRACTPHARMA
Triumvira Immunologics to Participate in Four Healthcare Investor Conferences
12 Oct 2022 //
BUSINESSWIRE
Triumvira Presents Initial HER2-Positive Solid Tumor Clinical Data at ESMO
12 Sep 2022 //
BUSINESSWIRE
Triumvira to Present Data from Ongoing Phase 1/2 Trial with T Cell Therapy
06 Sep 2022 //
BUSINESSWIRE
Triumvira Immunologics Completes Extension of Series A Financing
17 Mar 2022 //
BUSINESSWIRE
Triumvira Announces Data from Gastric Cancer Preclinical Study to be at SITC
13 Nov 2021 //
BUSINESSWIRE
First Patient is Dosed with Triumvira`s Invg TAC-T Cell Adoptive Immunotherapy
21 Sep 2021 //
CONTRACTPHARMA
Triumvira Doses 1st Patient with TAC-T Cell Therapy Using Lonza Cocoon Platform
21 Sep 2021 //
BUSINESSWIRE
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Trial
20 Sep 2021 //
BIOSPACE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.